Locations:
SearchA Cleveland Clinic oncologist has a few ideas
Image content: This image is available to view online.
View image online (https://assets.clevelandclinic.org/transform/1208341b-6693-4b15-88f3-d88db354fffd/killer-t-cells-surround-a-cancer-cell_650x450_jpg)
killer-t-cells-surround-a-cancer-cell_650x450
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Image content: This image is available to view online.
View image online (https://assets.clevelandclinic.org/transform/7c2f2304-c76f-4e21-9064-6ef36638dff3/Shepard_150x179_jpg)
Dale Shepard, MD, PhD
Web entrepreneur and philanthropist Sean Parker’s recent $250 million donation to fund collaborative cancer immunotherapy research is meant to accelerate progress in this promising field.
Cleveland Clinic Cancer Center oncologist Dale Shepard, MD, PhD, has some suggestions for how to spend this windfall. In this guest commentary for Everyday Health, Dr. Shepard, who directs the Cancer Center’s phase 1 clinical trials and sarcoma programs, recommends three steps to maximize the effectiveness of Parker’s gift.
Advertisement
Advertisement
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Global R&D efforts expanding first-line and relapse therapy options for patients
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
A case study on the value of access to novel therapies through clinical trials
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456
Key learnings from DESTINY trials
Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients